All Oncology News

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

A preclinical study has shown promising steps toward tackling drug resistance in hematologic malignancies using sequential dosing of drugs targeted against vulnerabilities that emerge as a result of tumor evolution

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

Does Medicare coverage for patients with cancer match up to what they actually want covered? There appears to be a mismatch between covered benefits and beneficiary preferences that involves quality of life and financial burden of care, according to a study from Duke University.

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

Increasingly, payers and patients are demanding that hospital-based oncology practices take a patient-centered approach in delivering care, with a specific focus on offering some form of financial assistance services to their patients, according to findings from the Association of Community Cancer Centers' "2014 Trends in Cancer Programs" survey.

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.

Don't look now but a consensus that bundled payments is the best payment reform strategy is emerging, and it's expected that many pilot and demonstration projects will start soon.

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

A report issued by the Council for Affordable Quality Healthcare (CAQH) suggests that if providers and health plans converted fully from manual to electronic transactions, it could result in an additional estimated savings of $8.1 billion for the healthcare industry.

The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

Treatment with KTE-C19, a CD19-targeted CAR-modified T cell therapy, demonstrated an objective response rate of 92% in patients with advanced B-cell malignancies.

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

Medicaid patients in states that pay more for office visits had an increased likelihood of being screened for cancer, according to results of a study published in CANCER.

How much physicians get paid is increasingly determined by a payment formula that penalizes doctors whose patients are more expensive-even when those higher costs stem from services that other doctors perform says a new report from the Center for Healthcare Quality and Payment Reform.

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.